Eisai projects $7B in sales by 2030 for new Alzheimer's drug

Zachary Brennan

Senior Editor

Eisai and Biogen’s newly approved Alzheimer’s drug Leqembi (lecanemab) is looking to do what its amyloid-targeted predecessor, Biogen’s Aduhelm (aducanumab), has yet to accomplish …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eisai projects $7B in sales by 2030 for new Alzheimer's drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

ADCs from a decade-old Singapore biotech find new life with $187M

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Ei­sai projects $7B in sales by 2030 for new Alzheimer's drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Eisai projects $7B in sales by 2030 for new Alzheimer's drug